O	O	O	0	10	Inhibition	Inhibition	B-NP	NN	O	0	ROOT	O
O	O	O	11	13	of	of	B-PP	IN	O	1	NMOD	O
T4	B-Entity	B-Entity	14	16	NF	NF	B-NP	NN	B-protein	7	NMOD	B-protein
T4	I-Entity	I-Entity	16	17	-	-	B-NP	HYPH	I-protein	7	NMOD	I-protein
T4	I-Entity	I-Entity	17	22	kappa	kappa	I-NP	NN	I-protein	7	NMOD	I-protein
T4	I-Entity	I-Entity	23	24	B	B	I-NP	NN	I-protein	7	NMOD	I-protein
O	O	O	25	35	activation	activation	I-NP	NN	O	2	PMOD	O
O	O	O	36	38	in	in	B-PP	IN	O	1	NMOD	O
O	O	O	39	44	human	human	B-NP	JJ	B-cell_line	13	NMOD	B-cell_line
O	O	O	45	46	T	T	I-NP	NN	I-cell_line	13	NMOD	I-cell_line
O	O	O	46	47	-	-	B-NP	HYPH	I-cell_line	13	NMOD	I-cell_line
O	O	O	47	51	cell	cell	I-NP	NN	I-cell_line	13	NMOD	I-cell_line
O	O	O	52	57	lines	line	I-NP	NNS	I-cell_line	8	PMOD	I-cell_line
O	O	O	58	60	by	by	B-PP	IN	O	1	NMOD	O
O	O	O	61	81	anetholdithiolthione	anetholdithiolthione	B-NP	NN	O	14	PMOD	O
O	O	O	81	82	.	.	O	.	O	1	P	O

T5	B-Entity	B-Entity	84	91	Nuclear	Nuclear	B-NP	JJ	B-protein	8	NMOD	B-protein
T5	I-Entity	I-Entity	92	98	factor	factor	I-NP	NN	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	99	100	(	(	O	(	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	100	102	NF	NF	B-NP	NN	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	102	103	)	)	O	)	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	103	104	-	-	B-NP	HYPH	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	104	109	kappa	kappa	I-NP	NN	I-protein	8	NMOD	I-protein
T5	I-Entity	I-Entity	110	111	B	B	I-NP	NN	I-protein	9	SUB	I-protein
O	O	O	112	114	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	115	116	a	a	B-NP	DT	O	15	NMOD	O
O	O	O	117	122	redox	redox	I-NP	NN	B-protein	15	NMOD	B-protein
O	O	O	123	132	sensitive	sensitive	I-NP	JJ	I-protein	15	NMOD	I-protein
O	O	O	133	142	cytosolic	cytosolic	I-NP	JJ	I-protein	15	NMOD	I-protein
O	O	O	143	156	transcription	transcription	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	O	157	163	factor	factor	I-NP	NN	I-protein	9	PRD	I-protein
O	O	O	163	164	.	.	O	.	O	9	P	O

O	O	O	165	170	Redox	Redox	B-NP	NN	O	2	NMOD	O
O	O	O	171	181	regulation	regulation	I-NP	NN	O	8	SUB	O
O	O	O	182	184	of	of	B-PP	IN	O	2	NMOD	O
T6	B-Entity	B-Entity	185	187	NF	NF	B-NP	NN	B-protein	7	NMOD	B-protein
T6	I-Entity	I-Entity	187	188	-	-	B-NP	HYPH	I-protein	7	NMOD	I-protein
T6	I-Entity	I-Entity	188	193	kappa	kappa	I-NP	NN	I-protein	7	NMOD	I-protein
T6	I-Entity	I-Entity	194	195	B	B	I-NP	NN	I-protein	3	PMOD	I-protein
O	O	O	196	199	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	200	204	been	be	I-VP	VBN	O	8	VC	O
O	O	O	205	215	implicated	implicate	I-VP	VBN	O	9	VC	O
O	O	O	216	218	in	in	B-PP	IN	O	10	VMOD	O
O	O	O	219	222	the	the	B-NP	DT	O	13	NMOD	O
O	O	O	223	233	activation	activation	I-NP	NN	O	11	PMOD	O
O	O	O	234	236	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	237	240	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	241	246	human	human	I-NP	JJ	O	17	NMOD	O
O	O	O	247	253	immuno	immuno	I-NP	NN	O	20	NMOD	O
O	O	O	253	254	-	-	O	HYPH	O	20	NMOD	O
O	O	O	254	264	deficiency	deficiency	B-NP	NN	O	20	NMOD	O
O	O	O	265	270	virus	virus	I-NP	NN	O	14	PMOD	O
O	O	O	271	272	(	(	O	(	O	23	DEP	O
O	O	O	272	275	HIV	HIV	B-NP	NN	O	23	DEP	O
O	O	O	275	276	)	)	O	)	O	20	NMOD	O
O	O	O	276	277	.	.	O	.	O	8	P	O

O	O	O	278	287	Therefore	Therefore	B-ADVP	RB	O	10	VMOD	O
O	O	O	287	288	,	,	O	,	O	10	P	O
O	O	O	289	299	inhibition	inhibition	B-NP	NN	O	10	SUB	O
O	O	O	300	302	of	of	B-PP	IN	O	3	NMOD	O
T7	B-Entity	B-Entity	303	305	NF	NF	B-NP	NN	B-protein	9	NMOD	B-protein
T7	I-Entity	I-Entity	305	306	-	-	B-NP	HYPH	I-protein	9	NMOD	I-protein
T7	I-Entity	I-Entity	306	311	kappa	kappa	I-NP	NN	I-protein	9	NMOD	I-protein
T7	I-Entity	I-Entity	312	313	B	B	I-NP	NN	I-protein	9	NMOD	I-protein
O	O	O	314	324	activation	activation	I-NP	NN	O	4	PMOD	O
O	O	O	325	328	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	329	331	be	be	I-VP	VB	O	10	VC	O
O	O	O	332	334	an	an	B-NP	DT	O	14	NMOD	O
O	O	O	335	344	effective	effective	I-NP	JJ	O	14	NMOD	O
O	O	O	345	353	strategy	strategy	I-NP	NN	O	11	PRD	O
O	O	O	354	357	for	for	B-PP	IN	O	14	NMOD	O
O	O	O	358	366	acquired	acquire	B-NP	VBN	O	19	NMOD	O
O	O	O	367	383	immunodeficiency	immunodeficiency	I-NP	NN	O	19	NMOD	O
O	O	O	384	392	syndrome	syndrome	I-NP	NN	O	19	NMOD	O
O	O	O	393	400	therapy	therapy	I-NP	NN	O	15	PMOD	O
O	O	O	400	401	.	.	O	.	O	10	P	O

O	O	O	402	422	Anetholdithiolthione	Anetholdithiolthione	B-NP	NN	O	23	NMOD	O
O	O	O	423	424	(	(	O	(	O	11	DEP	O
O	O	O	424	427	ADT	ADT	B-NP	NN	O	10	NMOD	O
O	O	O	427	428	,	,	O	,	O	6	P	O
O	O	O	429	430	5	5	B-NP	CD	O	6	AMOD	O
O	O	O	430	431	-	-	B-NP	HYPH	O	3	P	O
O	O	O	431	432	[	[	B-NP	(	O	10	NMOD	O
O	O	O	432	433	p	p	I-NP	NN	O	10	NMOD	O
O	O	O	433	434	-	-	I-NP	HYPH	O	10	P	O
O	O	O	434	447	methoxyphenyl	methoxyphenyl	I-NP	NN	O	11	DEP	O
O	O	O	447	448	]	]	O	)	O	1	NMOD	O
O	O	O	448	449	-	-	B-NP	HYPH	O	23	P	O
O	O	O	449	451	3H	3H	I-NP	NN	O	23	NMOD	O
O	O	O	451	452	-	-	I-NP	HYPH	O	23	P	O
O	O	O	452	453	1	1	I-NP	CD	O	23	NMOD	O
O	O	O	453	454	,	,	I-NP	,	O	23	P	O
O	O	O	454	455	2	2	I-NP	CD	O	23	NMOD	O
O	O	O	455	456	-	-	I-NP	HYPH	O	23	NMOD	O
O	O	O	456	463	dithiol	dithiol	I-NP	NN	O	23	NMOD	O
O	O	O	463	464	-	-	B-NP	HYPH	O	23	P	O
O	O	O	464	465	3	3	I-NP	CD	O	23	NMOD	O
O	O	O	465	466	-	-	I-NP	HYPH	O	23	P	O
O	O	O	466	472	thione	thione	I-NP	NN	O	25	SUB	O
O	O	O	472	473	)	)	O	)	O	23	NMOD	O
O	O	O	474	476	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	477	479	an	an	B-NP	DT	O	27	NMOD	O
O	O	O	480	491	antioxidant	antioxidant	I-NP	NN	O	25	PRD	O
O	O	O	492	497	which	which	B-NP	WDT	O	27	NMOD	O
O	O	O	498	501	has	have	B-VP	VBZ	O	28	SBAR	O
O	O	O	502	506	been	be	I-VP	VBN	O	29	VC	O
O	O	O	507	511	used	use	I-VP	VBN	O	30	VC	O
O	O	O	512	514	to	to	I-VP	TO	O	33	VMOD	O
O	O	O	515	522	protect	protect	I-VP	VB	O	31	VMOD	O
O	O	O	523	530	against	against	B-PP	IN	O	33	VMOD	O
O	O	O	531	544	acetaminophen	acetaminophen	B-NP	NN	O	41	NMOD	O
O	O	O	544	545	-	-	B-NP	HYPH	O	35	P	O
O	O	O	546	549	and	and	I-NP	CC	O	35	NMOD	O
O	O	O	550	554	CCl4	CCl4	I-NP	NN	O	41	NMOD	O
O	O	O	554	555	-	-	B-NP	HYPH	O	41	NMOD	O
O	O	O	555	562	induced	induce	I-NP	VBN	O	41	NMOD	O
O	O	O	563	577	hepatotoxicity	hepatotoxicity	I-NP	NN	O	47	NMOD	O
O	O	O	577	578	,	,	O	,	O	47	P	O
O	O	O	579	584	lipid	lipid	B-NP	NN	O	44	NMOD	O
O	O	O	585	597	peroxidation	peroxidation	I-NP	NN	O	47	NMOD	O
O	O	O	597	598	,	,	O	,	O	47	P	O
O	O	O	599	608	radiation	radiation	B-NP	NN	O	47	NMOD	O
O	O	O	609	615	injury	injury	I-NP	NN	O	34	PMOD	O
O	O	O	615	616	,	,	O	,	O	33	P	O
O	O	O	617	620	and	and	O	CC	O	33	VMOD	O
O	O	O	621	625	also	also	B-ADVP	RB	O	33	VMOD	O
O	O	O	626	629	has	have	B-VP	VBZ	O	29	VMOD	O
O	O	O	630	634	been	be	I-VP	VBN	O	51	VC	O
O	O	O	635	639	used	use	I-VP	VBN	O	52	VC	O
O	O	O	640	650	clinically	clinically	B-ADVP	RB	O	53	VMOD	O
O	O	O	651	653	as	as	B-PP	IN	O	53	VMOD	O
O	O	O	654	656	an	an	B-NP	DT	O	60	NMOD	O
O	O	O	657	661	anti	anti	I-NP	AFX	O	60	NMOD	O
O	O	O	661	662	-	-	I-NP	HYPH	O	60	NMOD	O
O	O	O	662	672	choleretic	choleretic	I-NP	JJ	O	60	NMOD	O
O	O	O	673	678	agent	agent	I-NP	NN	O	55	PMOD	O
O	O	O	678	679	.	.	O	.	O	25	P	O

O	O	O	680	683	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	684	691	present	present	I-NP	JJ	O	3	NMOD	O
O	O	O	692	697	study	study	I-NP	NN	O	4	SUB	O
O	O	O	698	706	examined	examine	B-VP	VBD	O	0	ROOT	O
O	O	O	707	710	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	711	717	effect	effect	I-NP	NN	O	4	OBJ	O
O	O	O	718	720	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	721	724	ADT	ADT	B-NP	NN	O	9	NMOD	O
O	O	O	725	737	pretreatment	pretreatment	I-NP	NN	O	7	PMOD	O
O	O	O	738	740	on	on	B-PP	IN	O	6	NMOD	O
T8	B-Entity	B-Entity	741	743	NF	NF	B-NP	NN	B-protein	15	NMOD	B-protein
T8	I-Entity	I-Entity	743	744	-	-	B-NP	HYPH	I-protein	15	NMOD	I-protein
T8	I-Entity	I-Entity	744	749	kappa	kappa	I-NP	NN	I-protein	15	NMOD	I-protein
T8	I-Entity	I-Entity	750	751	B	B	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	O	752	762	activation	activation	I-NP	NN	O	10	PMOD	O
O	O	O	763	765	in	in	B-PP	IN	O	15	NMOD	O
O	O	O	766	774	response	response	I-PP	NN	O	16	PMOD	O
O	O	O	775	777	to	to	I-PP	TO	O	16	PMOD	O
O	O	O	778	779	a	a	B-NP	DT	O	20	NMOD	O
O	O	O	780	787	variety	variety	I-NP	NN	O	16	PMOD	O
O	O	O	788	790	of	of	B-PP	IN	O	20	NMOD	O
O	O	O	791	798	stimuli	stimulus	B-NP	NNS	O	21	PMOD	O
O	O	O	799	803	such	such	B-PP	JJ	O	24	PMOD	O
O	O	O	804	806	as	as	I-PP	IN	O	22	NMOD	O
O	O	O	807	811	H2O2	H2O2	B-NP	NN	O	37	NMOD	O
O	O	O	811	812	,	,	O	,	O	37	P	O
O	O	O	813	820	phorbol	phorbol	B-NP	NN	O	29	NMOD	O
O	O	O	821	830	myristate	myristate	I-NP	NN	O	29	NMOD	O
O	O	O	831	838	acetate	acetate	I-NP	NN	O	37	NMOD	O
O	O	O	839	840	(	(	O	(	O	32	DEP	O
O	O	O	840	843	PMA	PMA	B-NP	NN	O	32	DEP	O
O	O	O	843	844	)	)	O	)	O	29	NMOD	O
O	O	O	845	847	or	or	O	CC	O	37	NMOD	O
T1	B-Protein	B-Protein	848	853	tumor	tumor	B-NP	NN	B-protein	37	NMOD	B-protein
T1	I-Protein	I-Protein	854	862	necrosis	necrosis	I-NP	NN	I-protein	37	NMOD	I-protein
T1	I-Protein	I-Protein	863	869	factor	factor	I-NP	NN	I-protein	37	NMOD	I-protein
T1	I-Protein	I-Protein	870	875	alpha	alpha	I-NP	NN	I-protein	24	PMOD	I-protein
O	O	O	876	877	(	(	O	(	O	41	DEP	O
T2	B-Protein	B-Protein	877	880	TNF	TNF	B-NP	NN	B-protein	40	NMOD	B-protein
T2	I-Protein	I-Protein	881	886	alpha	alpha	I-NP	NN	I-protein	41	DEP	I-protein
O	O	O	886	887	)	)	O	)	O	37	NMOD	O
O	O	O	887	888	.	.	O	.	O	4	P	O

O	O	O	889	892	PMA	PMA	B-NP	NN	O	4	NMOD	O
O	O	O	893	896	and	and	O	CC	O	4	NMOD	O
T3	B-Protein	B-Protein	897	900	TNF	TNF	B-NP	NN	B-protein	4	NMOD	B-protein
T3	I-Protein	I-Protein	901	906	alpha	alpha	I-NP	NN	I-protein	5	SUB	I-protein
O	O	O	907	914	induced	induce	B-VP	VBD	O	0	ROOT	O
O	O	O	915	925	activation	activation	B-NP	NN	O	5	OBJ	O
O	O	O	926	928	of	of	B-PP	IN	O	6	NMOD	O
T9	B-Entity	B-Entity	929	930	(	(	O	(	O	10	DEP	O
T9	I-Entity	I-Entity	930	932	NF	NF	B-NP	NN	O	10	DEP	O
T9	I-Entity	I-Entity	932	933	)	)	O	)	O	13	NMOD	O
T9	I-Entity	I-Entity	933	934	-	-	B-NP	HYPH	O	13	NMOD	O
T9	I-Entity	I-Entity	934	939	kappa	kappa	I-NP	NN	O	13	NMOD	O
T9	I-Entity	I-Entity	940	941	B	B	I-NP	NN	O	7	PMOD	O
O	O	O	942	944	in	in	B-PP	IN	O	5	VMOD	O
O	O	O	945	950	human	human	B-NP	JJ	B-cell_line	19	NMOD	B-cell_line
O	O	O	951	957	Jurkat	Jurkat	I-NP	NN	I-cell_line	19	NMOD	I-cell_line
O	O	O	958	959	T	T	I-NP	NN	I-cell_line	19	NMOD	I-cell_line
O	O	O	959	960	-	-	B-NP	HYPH	I-cell_line	19	NMOD	I-cell_line
O	O	O	960	965	cells	cell	I-NP	NNS	I-cell_line	14	PMOD	I-cell_line
O	O	O	966	969	was	be	B-VP	VBD	O	5	VMOD	O
O	O	O	970	979	partially	partially	I-VP	RB	O	20	VMOD	O
O	O	O	980	989	inhibited	inhibit	I-VP	VBN	O	20	VC	O
O	O	O	990	992	by	by	B-PP	IN	O	22	VMOD	O
O	O	O	993	996	ADT	ADT	B-NP	NN	O	31	NMOD	O
O	O	O	997	998	(	(	O	(	O	30	DEP	O
O	O	O	998	999	0	0	B-NP	CD	O	30	DEP	O
O	O	O	999	1000	.	.	O	.	O	30	P	O
O	O	O	1000	1001	1	1	B-NP	CD	O	29	NMOD	O
O	O	O	1002	1004	mM	mM	I-NP	NN	O	30	DEP	O
O	O	O	1004	1005	)	)	O	)	O	24	NMOD	O
O	O	O	1006	1018	pretreatment	pretreatment	B-NP	NN	O	23	PMOD	O
O	O	O	1018	1019	.	.	O	.	O	5	P	O

O	O	O	1020	1023	ADT	ADT	B-NP	NN	O	9	SUB	O
O	O	O	1024	1025	(	(	O	(	O	7	DEP	O
O	O	O	1025	1026	0	0	B-NP	CD	O	6	NMOD	O
O	O	O	1026	1027	.	.	O	.	O	6	NMOD	O
O	O	O	1027	1028	1	1	B-NP	CD	O	6	NMOD	O
O	O	O	1029	1031	mM	mM	I-NP	NN	O	7	DEP	O
O	O	O	1031	1032	)	)	O	)	O	1	NMOD	O
O	O	O	1033	1037	also	also	B-ADVP	RB	O	9	VMOD	O
O	O	O	1038	1047	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	O	1048	1052	H2O2	H2O2	B-NP	NN	O	12	NMOD	O
O	O	O	1053	1060	induced	induced	I-NP	JJ	O	12	NMOD	O
O	O	O	1061	1071	activation	activation	I-NP	NN	O	9	OBJ	O
O	O	O	1072	1074	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	1075	1078	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	1079	1092	transcription	transcription	I-NP	NN	B-protein	16	NMOD	B-protein
O	O	O	1093	1099	factor	factor	I-NP	NN	I-protein	13	PMOD	I-protein
O	O	O	1100	1102	in	in	B-PP	IN	O	12	NMOD	O
O	O	O	1103	1106	the	the	B-NP	DT	O	25	NMOD	O
O	O	O	1107	1115	peroxide	peroxide	I-NP	NN	B-cell_line	25	NMOD	B-cell_line
O	O	O	1116	1125	sensitive	sensitive	I-NP	JJ	I-cell_line	25	NMOD	I-cell_line
O	O	O	1126	1131	human	human	I-NP	JJ	I-cell_line	25	NMOD	I-cell_line
O	O	O	1132	1140	Wurzburg	Wurzburg	I-NP	NN	I-cell_line	25	NMOD	I-cell_line
O	O	O	1141	1142	T	T	I-NP	NN	I-cell_line	25	NMOD	I-cell_line
O	O	O	1142	1143	-	-	B-VP	HYPH	I-cell_line	25	NMOD	I-cell_line
O	O	O	1143	1148	cells	cell	B-NP	NNS	I-cell_line	17	PMOD	I-cell_line
O	O	O	1148	1149	.	.	O	.	O	9	P	O

O	O	O	1150	1161	Furthermore	Furthermore	B-ADVP	RB	O	7	VMOD	O
O	O	O	1161	1162	,	,	O	,	O	7	P	O
O	O	O	1163	1166	ADT	ADT	B-NP	NN	O	7	SUB	O
O	O	O	1167	1174	treated	treat	I-NP	VBN	O	3	NMOD	O
O	O	O	1175	1183	Wurzburg	Wurzburg	I-NP	NN	B-cell_line	6	NMOD	B-cell_line
O	O	O	1184	1189	cells	cell	I-NP	NNS	I-cell_line	3	NMOD	I-cell_line
O	O	O	1190	1193	had	have	B-VP	VBD	O	0	ROOT	O
O	O	O	1194	1207	significantly	significantly	B-NP	RB	O	9	AMOD	O
O	O	O	1208	1214	higher	high	I-NP	JJR	O	11	NMOD	O
T10	B-Entity	B-Entity	1215	1226	glutathione	glutathione	I-NP	NN	O	11	NMOD	O
O	O	O	1227	1233	levels	level	I-NP	NNS	O	7	OBJ	O
O	O	O	1234	1236	as	as	B-PP	IN	O	7	VMOD	O
O	O	O	1237	1245	compared	compare	B-PP	VBN	O	12	SBAR	O
O	O	O	1246	1250	with	with	B-PP	IN	O	13	VMOD	O
O	O	O	1251	1260	untreated	untreated	B-NP	JJ	B-cell_type	16	NMOD	B-cell_type
O	O	O	1261	1266	cells	cell	I-NP	NNS	I-cell_type	14	PMOD	I-cell_type
O	O	O	1266	1267	.	.	O	.	O	7	P	O

O	O	O	1268	1272	H2O2	H2O2	B-NP	NN	O	4	NMOD	O
O	O	O	1273	1280	induced	induce	B-VP	VBD	O	4	NMOD	O
O	O	O	1281	1286	lipid	lipid	B-NP	NN	O	4	NMOD	O
O	O	O	1287	1299	peroxidation	peroxidation	I-NP	NN	O	8	SUB	O
O	O	O	1300	1302	in	in	B-PP	IN	O	4	NMOD	O
O	O	O	1303	1311	Wurzburg	Wurzburg	B-NP	NN	B-cell_line	7	NMOD	B-cell_line
O	O	O	1312	1317	cells	cell	I-NP	NNS	I-cell_line	5	PMOD	I-cell_line
O	O	O	1318	1321	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1322	1332	remarkably	remarkably	I-VP	RB	O	8	VMOD	O
O	O	O	1333	1342	inhibited	inhibit	I-VP	VBN	O	8	VC	O
O	O	O	1343	1345	by	by	B-PP	IN	O	10	VMOD	O
O	O	O	1346	1349	ADT	ADT	B-NP	NN	O	13	NMOD	O
O	O	O	1350	1362	pretreatment	pretreatment	I-NP	NN	O	11	PMOD	O
O	O	O	1362	1363	.	.	O	.	O	8	P	O

O	O	O	1364	1367	ADT	ADT	B-NP	NN	O	7	NMOD	O
O	O	O	1367	1368	,	,	O	,	O	7	P	O
O	O	O	1369	1370	a	a	B-NP	DT	O	7	NMOD	O
O	O	O	1371	1374	pro	pro	I-NP	AFX	B-DNA	7	NMOD	B-DNA
O	O	O	1374	1375	-	-	I-NP	HYPH	O	7	NMOD	O
T11	B-Entity	B-Entity	1375	1386	glutathione	glutathione	I-NP	NN	O	7	NMOD	O
O	O	O	1387	1398	antioxidant	antioxidant	I-NP	NN	O	9	SUB	O
O	O	O	1398	1399	,	,	O	,	O	7	P	O
O	O	O	1400	1403	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	1404	1412	observed	observe	I-VP	VBN	O	9	VC	O
O	O	O	1413	1415	to	to	I-VP	TO	O	12	VMOD	O
O	O	O	1416	1418	be	be	I-VP	VB	O	10	VMOD	O
O	O	O	1419	1426	capable	capable	B-ADJP	JJ	O	12	PRD	O
O	O	O	1427	1429	of	of	B-PP	IN	O	13	AMOD	O
O	O	O	1430	1440	modulating	modulate	B-VP	VBG	O	14	PMOD	O
T12	B-Entity	B-Entity	1441	1443	NF	NF	B-NP	NN	B-protein	20	NMOD	B-protein
T12	I-Entity	I-Entity	1443	1444	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T12	I-Entity	I-Entity	1444	1449	kappa	kappa	I-NP	NN	I-protein	20	NMOD	I-protein
T12	I-Entity	I-Entity	1450	1451	B	B	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	O	1452	1462	activation	activation	I-NP	NN	O	15	OBJ	O
O	O	O	1462	1463	.	.	O	.	O	9	P	O
